Since JAK2 directly phosphorylates PP2A inactivating PP2A [151], combination of JAK2 inhibitors and PP2A activators could be beneficial in CML treatment. The gene discussed is JAK2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.